Burling Wealth Partners LLC added 929 shares of Amgen to its portfolio in Q4, worth about $242,000—a modest but calculated ...

Alvotech faces challenges with potential tariffs and profitability, despite strong revenue growth and a robust pipeline. See ...

We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Amgen (NASDAQ:AMGN) is set to report its Q1 earnings results on Thursday, May 1st, after the market closes. Street ...

Amgen is preparing to release its Q1 2025 earnings, with analysts expecting $4.18 EPS and $8.05 billion in revenue. In its ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Trump's 100th Day, April Jobs Report, Inflation Data, First Quarter GDP, Earnings from Microsoft, Meta Platforms, Apple, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Here are the top 5 biosimilar articles for the week of April 21, 2025. Number 5: Trastuzumab biosimilars saw significant ...

TScan Therapeutics, Inc.’s TCRX share price has dipped by 5.81%, which has investors questioning if this is right time to buy ...